Search - tctmd.com

Displaying 1 - 19 of 19

Sort: Relevancy | Date

Presentation TCT 2022

Discussion - What does this Field Need Next?

Presenter: Felix Mahfoud

September 19, 2022

Presentation TCT 2022

Who Should be Treated with uRDN?

Presenter: Naomi Fisher

September 19, 2022

Presentation TCT 2022

Discussion - Key Takeaways from the RADIANCE Clinical Program

Presenter: Felix Mahfoud

September 19, 2022

Presentation TCT 2022

Late-Breaking Evidence from RADIANCE II

Presenter: Michel Azizi

September 19, 2022

Presentation TCT 2022

Introduction and Objectives

Presenter: Felix Mahfoud

September 19, 2022

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

Presentation TCT 2022

NEXT STEPS: How Will Renal Denervation be Implemented in Practice?

Presenter: Naomi Fisher

September 18, 2022

Presentation TCT 2022

Clinical Implications of RADIANCE II and Recent Renal Denervation Trials: A Clinician’s Perspective

Presenter: Patrick O'Gara

September 18, 2022

News Conference News TCT 2022

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

Todd Neale

September 18, 2022

Presentation TCT 2022

Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

Presenter: Deepak Bhatt

September 18, 2022

Presentation TCT 2022

Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Primary Results of the Randomized, Sham-Controlled RADIANCE II Pivotal Trial

Presenter: Ajay Kirtane

September 18, 2022

Presentation TCT 2022

Update on the RADIANCE Clinical Trials Program (Ultra-Sound Renal Denervation)

Presenter: Naomi Fisher

September 17, 2022

Presentation TCT 2022

Update on the SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation)

Presenter: David Kandzari

September 17, 2022

Presentation TCT 2022

TCT 215: Association between Renal Sympathetic Denervation and Arterial Stiffness: the ASORAS Study.

Presenter: Victor Zeijen

September 17, 2022

Presentation TCT 2022

TCT 214: Single Ablation Renal Denervation – The RADAR Study Experience with the Metavention iRF System

Presenter: Horst Sievert

September 17, 2022

Presentation TCT 2022

TCT 212: Twenty-Four Month Results in Patients with Resistant Hypertension After Endovascular Ultrasound Renal Denervation in the RADIANCE-HTN TRIO Trial

Presenter: Roland Schmieder

September 17, 2022

Presentation TCT 2022

TCT 213: Impact of Cardiac Neuromodulation Therapy (CNT) on Systolic Blood Pressure and Pulse Pressure in Hypertensive Patients Indicated for a Pacemaker: Results of a Crossover Study

Presenter: Daniel Burkhoff

September 17, 2022

Presentation TCT 2022

TCT 210: Long-term blood pressure results after renal sympathetic denervation using endovascular ultrasound

Presenter: Karl Fengler

September 17, 2022

News Conference News TCT 2022

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Shelley Wood

September 07, 2022

Advertisement

Discussion - What does this Field Need Next?

Who Should be Treated with uRDN?

Discussion - Key Takeaways from the RADIANCE Clinical Program

Late-Breaking Evidence from RADIANCE II

Introduction and Objectives

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

NEXT STEPS: How Will Renal Denervation be Implemented in Practice?

Clinical Implications of RADIANCE II and Recent Renal Denervation Trials: A Clinician’s Perspective

RADIANCE II Confirms Ultrasound-Based Renal Denervation Lowers BP

Long-Term Outcomes Following Catheter-Based Renal Denervation in Patients With Uncontrolled Hypertension: 3-Year Follow-up of the SYMPLICITY HTN-3 Trial

Endovascular Ultrasound Renal Denervation to Treat Uncontrolled Hypertension: Primary Results of the Randomized, Sham-Controlled RADIANCE II Pivotal Trial

Update on the RADIANCE Clinical Trials Program (Ultra-Sound Renal Denervation)

Update on the SPYRAL Clinical Trials Program (Radiofrequency Renal Denervation)

TCT 215: Association between Renal Sympathetic Denervation and Arterial Stiffness: the ASORAS Study.

TCT 214: Single Ablation Renal Denervation – The RADAR Study Experience with the Metavention iRF System

TCT 212: Twenty-Four Month Results in Patients with Resistant Hypertension After Endovascular Ultrasound Renal Denervation in the RADIANCE-HTN TRIO Trial

TCT 213: Impact of Cardiac Neuromodulation Therapy (CNT) on Systolic Blood Pressure and Pulse Pressure in Hypertensive Patients Indicated for a Pacemaker: Results of a Crossover Study

TCT 210: Long-term blood pressure results after renal sympathetic denervation using endovascular ultrasound

New Faces, New Formats, New Tech: What to Expect From TCT 2022

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content